MarketScanners

EXEL Climbing Ahead of FDA Decision

Long
NASDAQ:EXEL   Exelixis, Inc
151 views
0
$EXEL shares starting to break-out.FDA decision scheduled to Nov. 29. "optimists like cabozantinib's chances for approval" says Motley Fool. Looks like negative over-all market conditions weighing in on the stock move. Watch this one!

http://www.fool.com/investing/general/20...

Comments